PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32002592-1 2020 PURPOSE: This study aimed to determine if major gene mutations including in KRAS, SMAD4, TP53, and CDKN2A were related to imaging phenotype using 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)-based radiomics in patients with pancreatic ductal adenocarcinoma (PDAC). Fluorodeoxyglucose F18 146-168 cyclin dependent kinase inhibitor 2A Homo sapiens 99-105 32002592-1 2020 PURPOSE: This study aimed to determine if major gene mutations including in KRAS, SMAD4, TP53, and CDKN2A were related to imaging phenotype using 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)-based radiomics in patients with pancreatic ductal adenocarcinoma (PDAC). Fluorodeoxyglucose F18 170-173 cyclin dependent kinase inhibitor 2A Homo sapiens 99-105 32695371-0 2020 Fluorodeoxyglucose positron emission tomography/computed tomography identifying pericardial metastasis from early-stage p16-positive oropharyngeal cancer. Fluorodeoxyglucose F18 0-18 cyclin dependent kinase inhibitor 2A Homo sapiens 120-123 32294581-10 2020 For p16+ cases, regional specificity was 76.2% versus 91.1% (p = 0.0003), local PPV was 0 versus 30% (p = 0.06) and the regional PPV was 12% versus 35% (p = 0.06) for FDG-PET/CT scans performed at <=12 weeks versus >12 weeks. Fluorodeoxyglucose F18 167-170 cyclin dependent kinase inhibitor 2A Homo sapiens 4-7 32294581-12 2020 CONCLUSIONS: Metabolic response on post-treatment FDG-PET/CT has excellent NPV regardless of p16 status. Fluorodeoxyglucose F18 50-53 cyclin dependent kinase inhibitor 2A Homo sapiens 93-96 29496044-0 2018 Heterogeneity and irregularity of pretreatment 18F-fluorodeoxyglucose positron emission tomography improved prognostic stratification of p16-negative high-risk squamous cell carcinoma of the oropharynx. Fluorodeoxyglucose F18 47-69 cyclin dependent kinase inhibitor 2A Homo sapiens 137-140 29960060-0 2018 Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. Fluorodeoxyglucose F18 39-45 cyclin dependent kinase inhibitor 2A Homo sapiens 78-81 22330994-12 2012 In addition, patients with p16-positive tumors (score > 0) were more likely to be complete metabolic responders as assessed by the 3-month posttherapy 18 [F]-fluorodeoxyglucose positron emission tomography (FDG-PET)/computed tomograph compared with patients with p16-negative tumors (p = 0.03). Fluorodeoxyglucose F18 161-179 cyclin dependent kinase inhibitor 2A Homo sapiens 27-30